8-K: Nephros Reports Strong Q2 2025 Results, Sustains Profitability

Nephros, Inc. announced robust second-quarter 2025 financial results, achieving $4.4 million in net revenue and its third consecutive quarter of profitability.

Summary

• Net revenue for the second quarter of 2025 was $4.4 million, a 36% increase compared to $3.3 million in the second quarter of 2024.
• Net income for Q2 2025 was $237,000, a significant improvement from a net loss of ($289,000) in Q2 2024, marking the third consecutive quarter of profitability.
• Adjusted EBITDA for Q2 2025 was $355,000, compared to ($133,000) in the second quarter of 2024.
• For the six months ended June 30, 2025, net revenue was $9.3 million, up 37% from $6.8 million in the same period of 2024.
• Net income for the six months ended June 30, 2025, was $795,000, compared to a net loss of ($458,000) in the same period of 2024.
• Adjusted EBITDA for the six months ended June 30, 2025, was $1 million, compared to ($228,000) in the same period of 2024.
• Trailing 12-month revenue grew from $13.8 million to $16.7 million over the past two years.
• Programmatic sales reached an all-time high in Q2 2025, supported by a new installation and replacement program.
• The dialysis water segment achieved its second-highest performance on record and secured the largest dialysis filtration purchase order in company history.
• Active-site counts reached all-time highs across infection control, dialysis water, and commercial segments.
• Gross margin improved to 63% in Q2 2025 from 59% in Q2 2024, driven by reduced shipping costs and inventory reserve adjustments.
• Cash and cash equivalents were approximately $5.1 million as of June 30, 2025, up from $3.8 million as of December 31, 2024, and the company remains debt-free.

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong financial performance, including significant revenue growth, a shift from net loss to consistent profitability for three consecutive quarters, improved gross margins, and strong operational metrics like record programmatic sales and active site counts. The company also increased its cash position and remains debt-free. These indicators point to robust health and positive momentum.

Positives

• Net revenue increased by 36% year-over-year in Q2 2025 to $4.4 million, demonstrating robust growth.
• Achieved net income of $237,000 in Q2 2025, a significant turnaround from a net loss of ($289,000) in Q2 2024, marking the third consecutive quarter of profitability.
• Adjusted EBITDA improved substantially to $355,000 in Q2 2025 from a loss of ($133,000) in Q2 2024.
• Year-to-date net revenue grew 37% to $9.3 million, and year-to-date net income reached $795,000.
• Trailing 12-month revenue increased from $13.8 million to $16.7 million over the past two years, indicating sustained growth.
• Programmatic sales reached an all-time high in Q2, driven by a successful installation and replacement program that fosters reliable reorder volume.
• The dialysis water segment recorded its second-highest performance ever and secured the largest dialysis filtration purchase order in company history.
• Active-site counts achieved all-time highs across all key segments: infection control, dialysis water, and commercial.
• Gross margin improved to 63% in Q2 2025 (from 59%) and 64% year-to-date (from 61%), attributed to lower shipping costs, inventory reserve adjustments, and a favorable product mix.
• Cash and cash equivalents increased to $5.1 million as of June 30, 2025, from $3.8 million at December 31, 2024, strengthening the balance sheet.
• The company remains debt-free, providing financial flexibility.

Negatives

• Selling, general and administrative expenses increased by 13% in Q2 2025 to $2.2 million, primarily due to higher sales commissions, employee bonuses, and stock-based compensation.
• Cost of goods sold increased by 21% in Q2 2025 to $1.6 million, although gross margin still improved.

Risks

• Ability to further develop the sales organization and realize increased revenues.
• Financial results based on emergency response sales can be outside of the company's control.
• Potential for U.S. tariffs to increase expenses.
• Impact of inflationary factors and other economic and competitive conditions.
• Availability of capital when needed.
• Dependence on third-party manufacturers and researchers.
• Impact of regulatory reforms.

Future Outlook

Management expresses confidence in the long-term outlook, anticipating sustained growth driven by market-leading technology and strategic focus. They believe unprecedented results in programmatic business and active customer sites underscore durable demand, reinforcing their confidence in future performance.

Management Comments

• Q2 2025 marked another strong quarter with net revenue of $4.4 million, an increase of $1.2 million, or 36% year-over-year. This performance builds on our momentum from Q1 and marks the third consecutive quarter of profitability.
• We believe these results reflect disciplined execution, operational excellence, and our consistent investment in growth-driving innovation.
• Over the past two years, we've grown trailing 12-month revenue from $13.8 million to $16.7 million—progress that highlights the strength of our programmatic business and expanding customer base.
• Our programmatic sales reached an all-time high in Q2, supported by the recent implementation of our installation and replacement program which has deepened customer integration and begun driving reliable reorder volume.
• During the second quarter, our dialysis water segment delivered its second-highest performance on record and secured the largest dialysis filtration purchase order in company history.
• Active-site counts reached all-time highs across infection control, dialysis water, and commercial segments.
• Our targeted additions to the sales-support team have broadened our reach and supported our deepened our focus on verticals beyond patient care.
• The coupling of market-leading technology with strategic focus continues to position Nephros for sustained growth.
• We believe our unprecedented results in programmatic business and active customer sites underscores durable demand, reinforcing our confidence in the long-term outlook.
• We are extremely pleased to show our third consecutive quarter of net income in the Company's history.

Industry Context

Nephros operates in the water technology sector, providing specialized filtration solutions for medical and commercial markets. The strong growth in programmatic sales and active sites suggests increasing demand for water safety and filtration solutions, potentially driven by heightened awareness, evolving regulatory requirements, or a focus on preventative health measures in healthcare and commercial settings. The company's strategic focus on expanding its customer base and diversifying into verticals beyond patient care indicates an effort to capture broader market opportunities within the water technology industry and reduce reliance on a single segment.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, consistent profitability, significant revenue growth, and increased cash position, which could lead to increased share value.
• Customers: Positive impact through deepened customer integration via the installation and replacement program, driving reliable reorder volume and suggesting satisfaction with products and services.
• Employees: Higher sales commissions and increased accrual for employee bonuses indicate a positive impact on sales and potentially other employees, reflecting the company's success.

Next Steps

• Nephros will host a conference call on August 7, 2025, at 4:30 PM ET to discuss financial results and provide a general business overview.
• An audio archive of the conference call will be available shortly after on the Nephros Investor Relations page.
• A replay of the conference call will be accessible until August 15, 2025.
• Future reports will be filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Reports on Form 10-Q.

Key Dates

Recommendation

The filing demonstrates exceptional financial and operational performance, including significant revenue growth, a sustained shift to profitability (third consecutive quarter), improved gross margins, and record programmatic sales and active customer sites. The company is debt-free and has increased its cash reserves. These strong fundamentals, coupled with management's confidence in durable demand and strategic growth initiatives, suggest a very positive outlook and strong investment potential.

Keywords

Water filtration, Medical technology, Commercial filtration, Dialysis water, Infection control, Water safety, Financial results, Q2 2025, Profitability, NEPH, Water treatment